A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis
Status:
Suspended
Trial end date:
2022-04-21
Target enrollment:
Participant gender:
Summary
This study is being conducted to determine how safe and how well tolerated LY3462817 is when
given to participants with psoriasis. Blood tests will be done to check how much LY3462817 is
in the bloodstream and how long the body takes to get rid of it. The study will last up to
one year and one month for each participant. As part of protocol addendum, this study is
additionally evaluating the safety and tolerability of LY3509754 in participants with
psoriasis. Blood tests will be done to check how much LY3509754 is in the bloodstream and how
long the body takes to get rid of it. The addendum will last up to 12 weeks for each
participant.